Progress of chimeric antigen receptor T-cell therapy for multiple myeloma
10.3760/cma.j.cn115356-20240328-00042
- VernacularTitle:嵌合抗原受体T细胞治疗多发性骨髓瘤研究进展
- Author:
Jingyuan MA
1
;
Mu HAO
Author Information
1. 中国医学科学院血液病医院（中国医学科学院血液学研究所） 实验血液学国家重点实验室 国家血液系统疾病临床医学研究中心 细胞生态海河实验室，天津 300020
- Keywords:
Multiple myeloma;
Chimeric antigen receptor T-cell;
Molecular targeted therapy;
Treatment outcome
- From:
Journal of Leukemia & Lymphoma
2024;33(5):265-269
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is the second most common hematologic malignancy. In recent years, the advent of a new generation of drugs including proteasome inhibitors and immunomodulatory drugs has significantly improved the prognosis of MM patients, extending the median survival to 3-6 years. Meanwhile, chimeric antigen receptor T-cell (CAR-T) immunotherapy has made great progress in treating relapsed/refractory MM, but the high relapse rate and short remission duration are still challenges for CAR-T therapy. Therefore, it is imperative to explore factors affecting the efficacy and safety of CAR-T therapy and optimize the treatment strategies. This article reviews the recent advances in CAR-T therapy for MM reported at the 65th American Society of Hematology (ASH) Annual Meeting in 2023.
